Lawsuit filed for Investors in Novo Nordisk A/S (NYSE: NVO) over alleged Securities Laws Violations

An investor, who purchased shares of Novo Nordisk A/S (NYSE: NVO), filed a lawsuit in the U.S. District Court for the District of New Jersey over alleged violations of Federal Securities Laws by Novo Nordisk A/S in connection with certain allegedly false and misleading statements

Investors who purchased a significant amount of shares of Novo Nordisk A/S (NYSE: NVO) between November 2, 2022 to December 19, 2024, have certain options and for certain investors are short and strict deadlines running. Deadline: March 25, 2025. NYSE: NVO investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Denmark based Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. Novo Nordisk A/S reported that its annual Total Revenue rose from over 176.95 billion DKK in 2022 to over 232.26 billion DKK in 2023, and that its Net Income increased from 55.52 billlion DKK in 2022 to over 83.68 billion DKK in 2023.

On December 20, 2024, Novo Nordisk announced the below-expected results of their "REDEFINE 1" trial, "a 68-week efficacy and safety trial investigating subcutaneous CagriSema." The trial showed that patients treated with CagriSema exhibited weight loss of 22.7% after 68 weeks, well short of Novo's targeted expectation of at least 25% weight loss. The press release further indicated that participant patients were permitted to modify their own dosage during the trial and, as a result, only 57.3% of patients treated with CagriSema were on the highest dosage contemplated by the study.

Shares of Novo Nordisk A/S (NYSE: NVO) declined from $148.15 per share on June 25, 2024, to as low as $78.17 per share on January 17, 2025.

According to the complaint the plaintiff alleges on behalf of purchasers of Novo Nordisk A/S (NYSE: NVO) common shares between November 2, 2022 to December 19, 2024, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between November 2, 2022 to December 19, 2024, the Defendants made materially false and misleading statements concerning Novo's REDEFINE-1 Study. The Complaint further alleges that on December 20, 2024, Defendants disclosed information that was directly related to their prior misrepresentations and material omissions concerning Novo's REDEFINE-1 Study and that this disclosure had the effect of correcting Defendants' prior false and/or misleading statements which, in turn, caused Novo's stock price to decline as investors reassessed the risks and benefits of investing in the Company.

Those who purchased shares of Novo Nordisk A/S (NYSE: NVO) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.